BioSpace News Archive

Health Canada maintains a list of unauthorized health products that may pose serious health risks so that Canadians can easily identify those they may have purchased and take appropriate action.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a worldwide license and research agreement with Philips, a global leader in health technology, to commercialize the ClearPoint ‘Maestro’ Brain Model.

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, February 25, 2021, at 4:30 p.m. E

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Christopher J. DeRespino as chief business officer, effective immediately.

Assertio Holdings, Inc. announced that it will release fourth quarter and full year 2020 financial results on Thursday, March 11, 2021, after the close of markets.

GBS Inc., a life sciences company that develops non-invasive, real-time point of care diagnostic tests for patients and their primary health practitioners, announced the execution of a sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to accelerate development of next-generation saliva-based diagnostic tests.

Agreement with the Amsterdam Skills Centre Establishes Second European Surgical Training Site for Senhance Digital Laparoscopy

Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler’ covid-19 recovery patients in Europe

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report fourth quarter and year ended Dec. 31, 2020 financial results following the close of U.S. financial markets on March 1.

Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Courtney Barton has joined the company as Chief Compliance Officer and Chief of Staff.